Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059306 · ClinicalTrials.gov registry record · Phase 3
Secondary Prevention of Small Subcortical Strokes Trial
A Phase 3 study, sponsored by University of British Columbia.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,020
- Enrollment target
NCT00059306: Completed Phase 3 study, sponsored by University of British Columbia.
NCT00059306 is a Phase 3 study that has completed, run by University of British Columbia. The registered enrollment target is 3,020 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (291% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00059306, a Phase 3 study, has completed, sponsored by University of British Columbia.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,020 participants
- Enrollment target
Study Summary
The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline. On July 21, 2011 the DSMB recommended terminating the anti platelet arm of the study due to an imbalance of overall and major non-CNS hemorrhagic SAE's and total deaths in the investigational anti platelet combination of aspirin + clopidogrel and an interim statistical analysis that demonstrated futility in the investigational anti platelet arm. It was recommended that patients be continued on standard care of aspirin mono therapy until their study close-out visit. Also, recommended the continuation and completion of the plood pressure arm following the protocol.
Interventions
- OTHER placebo
- DRUG aspirin
- DRUG clopidogrel
- OTHER Target of Blood Pressure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,020 participants |
| Start Date | 2003-02 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
What the finished NCT00059306 record still lists
NCT00059306 is an interventional study that assigns participants to a tested intervention. Its 3,020 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (291% higher).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00059306 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00059306 about?
NCT00059306 is a clinical study titled "Secondary Prevention of Small Subcortical Strokes Trial". The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline...
What is the current status of trial NCT00059306?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,020 participants. The study started on 2003-02. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00059306?
The interventions under investigation include: placebo (OTHER), aspirin (DRUG), clopidogrel (DRUG), Target of Blood Pressure (OTHER).
Who is sponsoring clinical trial NCT00059306?
This trial is sponsored by University of British Columbia, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00059306's enrollment target sits among peer trials
3,020 79th of 2000 higher than 1,922 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia